These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 25282448)

  • 1. Warfarin pharmacogenetics.
    Johnson JA; Cavallari LH
    Trends Cardiovasc Med; 2015 Jan; 25(1):33-41. PubMed ID: 25282448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
    Johnson JA; Caudle KE; Gong L; Whirl-Carrillo M; Stein CM; Scott SA; Lee MT; Gage BF; Kimmel SE; Perera MA; Anderson JL; Pirmohamed M; Klein TE; Limdi NA; Cavallari LH; Wadelius M
    Clin Pharmacol Ther; 2017 Sep; 102(3):397-404. PubMed ID: 28198005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genes affecting warfarin response-interactive or additive?
    Cavallari LH; Duarte JD
    J Clin Pharmacol; 2015 Mar; 55(3):258-60. PubMed ID: 25385663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
    Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
    Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients.
    Cho SM; Lee KY; Choi JR; Lee KA
    Yonsei Med J; 2016 May; 57(3):635-40. PubMed ID: 26996562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Warfarin pharmacogenetics: to genotype or not to genotype, that is the question.
    Cavallari LH; Nutescu EA
    Clin Pharmacol Ther; 2014 Jul; 96(1):22-4. PubMed ID: 24942399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementing Algorithm-Guided Warfarin Dosing in an Ethnically Diverse Patient Population Using Electronic Health Records and Preemptive CYP2C9 and VKORC1 Genetic Testing.
    Obeng AO; Kaszemacher T; Abul-Husn NS; Gottesman O; Vega A; Waite E; Myers K; Cho J; Bottinger EP; Ellis SB; Scott SA
    Clin Pharmacol Ther; 2016 Nov; 100(5):427-430. PubMed ID: 27393744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Warfarin pharmacogenetics.
    Limdi NA; Veenstra DL
    Pharmacotherapy; 2008 Sep; 28(9):1084-97. PubMed ID: 18752379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
    Ghozlan MF; Foad DA; Darwish YW; Saad AA
    Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the role of pharmacogenetics in optimization of warfarin dosing?
    Carnes CA
    Trends Cardiovasc Med; 2015 Jan; 25(1):42-3. PubMed ID: 25476743
    [No Abstract]   [Full Text] [Related]  

  • 12. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotype-guided coumarin dosing: where are we now and where do we need to go next?
    Baranova EV; Verhoef TI; Asselbergs FW; de Boer A; Maitland-van der Zee AH
    Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):509-22. PubMed ID: 25595525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Verification of pharmacogenomics-based algorithms to predict warfarin maintenance dose using registered data of Japanese patients.
    Sasano M; Ohno M; Fukuda Y; Nonen S; Hirobe S; Maeda S; Miwa Y; Yokoyama J; Nakayama H; Miyagawa S; Sawa Y; Fujio Y; Maeda M
    Eur J Clin Pharmacol; 2019 Jul; 75(7):901-911. PubMed ID: 30852642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.
    Arwood MJ; Deng J; Drozda K; Pugach O; Nutescu EA; Schmidt S; Duarte JD; Cavallari LH
    Clin Pharmacol Ther; 2017 May; 101(5):675-683. PubMed ID: 28032893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative performance of pharmacogenetics-based warfarin dosing algorithms derived from Caucasian, Asian, and mixed races in Thai population.
    Chumnumwat S; Yi K; Lucksiri A; Nosoongnoen W; Chindavijak B; Chulavatnatol S; Sarapakdi A; Nathisuwan S
    Cardiovasc Ther; 2018 Apr; 36(2):. PubMed ID: 29243335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
    Takeuchi M; Kobayashi T; Brandão LR; Ito S
    Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.
    Verhoef TI; Redekop WK; Daly AK; van Schie RM; de Boer A; Maitland-van der Zee AH
    Br J Clin Pharmacol; 2014 Apr; 77(4):626-41. PubMed ID: 23919835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Race influences warfarin dose changes associated with genetic factors.
    Limdi NA; Brown TM; Yan Q; Thigpen JL; Shendre A; Liu N; Hill CE; Arnett DK; Beasley TM
    Blood; 2015 Jul; 126(4):539-45. PubMed ID: 26024874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects.
    Hawcutt DB; Ghani AA; Sutton L; Jorgensen A; Zhang E; Murray M; Michael H; Peart I; Smyth RL; Pirmohamed M
    Pharmacogenomics J; 2014 Dec; 14(6):542-8. PubMed ID: 25001883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.